Last reviewed · How we verify
NCT05383547
Bortezomib for Treating Glomerular Diseases
NA trial testing Bortezomib in Bortezomib in 20 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 2 August 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bortezomib (bortezomib) — full drug profile →
Conditions studied
- Bortezomib — all drugs for Bortezomib →
- Glomerulonephritis — all drugs for Glomerulonephritis →
- MN — all drugs for MN →
- MPGN — all drugs for MPGN →
Sponsor
Ruijin Hospital
Who can join
Adults 18 to 65, any sex, with Bortezomib or Glomerulonephritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bortezomib is a proteasome inhibitor that inhibits autoantibody production, and reduces podocyte damage and mesangial hyperplasia caused by NF-κB activation in the kidney. Literature has reported that bortezomib can achieve a complete response rate of up to 38% in the treatment of glomerular diseases, but its safety and effectiveness remain to be assessed for the Chinese demographic. This study attempts to explore a new treatment plan for glomerular disease by observing the therapeutic effect of bortezomib on glomerular disease.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Treatment of IgA Nephropathy: A Rapidly Evolving Field.
El Karoui K, Fervenza FC, Fervenza FC, De Vriese AS. · · 2024 · cited 69× · PMID 37772889 · DOI 10.1681/asn.0000000000000242 -
IgA Nephropathy: Current Treatment and New Insights.
Petrou D, Kalogeropoulos P, Liapis G, Lionaki S. · · 2023 · cited 22× · PMID 37366657 · DOI 10.3390/antib12020040 -
New Insights and Future Perspectives of APRIL in IgA Nephropathy.
Muto M, Suzuki H, Suzuki Y. · · 2024 · cited 7× · PMID 39408691 · DOI 10.3390/ijms251910340 -
Expanding options of supportive care in IgA nephropathy.
Maixnerova D, Hartinger J, Tesar V. · · 2023 · cited 6× · PMID 38053975 · DOI 10.1093/ckj/sfad201 -
What is new in the pathogenesis and treatment of IgA glomerulonephritis.
Salvadori M, Rosso G. · · 2024 · cited 3× · PMID 39723359 · DOI 10.5527/wjn.v13.i4.98709 -
Biologics and Non-Biologics Immunosuppressive Treatments for IgA Nephropathy in Both Adults and Children.
Chiarenza DS, Verrina EE, La Porta E, Caridi G, et al · · 2024 · cited 2× · PMID 38730994 · DOI 10.3390/jcm13092465 -
Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis.
Swain S, Narayan RK, Mishra PR. · · 2024 · cited 1× · PMID 39239563 · DOI 10.3389/fcell.2024.1461278 -
Prospective Pilot Study of Plasma Cell-Targeted Therapy With Bortezomib in Refractory IgA Nephropathy.
Lin L, Ren H, Li X, Xie J, et al · · 2025 · PMID 40980670 · DOI 10.1016/j.ekir.2025.06.006
Verify or expand the search:
- PubMed search for NCT05383547
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bortezomib
Trials testing the same drug.
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
- NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05383547 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 31 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05383547.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing